Disclosure to EGX correcting the number of BoD meetings in the Annual BoD Report Regulatory DisclosuresBy adminMarch 22, 2021
Disclosure to EGX on GlaxoSmithKline S.A.E response to Rameda’s acquisition request Regulatory DisclosuresBy adminFebruary 9, 2021
Disclosure to EGX on Rameda expressing interest in the acquisition of GlaxoSmithKline S.A.E Regulatory DisclosuresBy adminFebruary 2, 2021
Disclosure to EGX on FRA approval of new a remuneration system Regulatory DisclosuresBy adminJanuary 12, 2021
Disclosure to EGX regarding the contact information for Investor Relations department Regulatory DisclosuresBy adminNovember 25, 2020
